PLGF 2 Human, Sf9

Recombinant Human Placental Growth Factor-2 (rhPlGF-2) is a protein that plays a crucial role in angiogenesis and arteriogenesis. It is a member of the vascular endothelial growth factor (VEGF) family and is primarily involved in the formation of new blood vessels. The “Sf9” in its name refers to the insect cell line used for its production, specifically the Spodoptera frugiperda (fall armyworm) cells.

The production of rhPlGF-2 involves the use of recombinant DNA technology. The gene encoding PlGF-2 is inserted into a baculovirus vector, which is then used to infect Sf9 cells. These cells are capable of producing large quantities of the protein, which can then be purified for research and therapeutic use.

PlGF-2 binds to the VEGF receptor-1 (VEGFR-1), also known as Flt-1, on the surface of endothelial cells. This binding stimulates the proliferation and migration of these cells, leading to the formation of new blood vessels. PlGF-2 is particularly important in pathological conditions where increased blood supply is needed, such as in wound healing, ischemic diseases, and cancer.

The therapeutic potential of rhPlGF-2 has been explored in various preclinical and clinical studies. For instance, it has been investigated for its ability to induce angiogenesis in ischemic tissues, such as in the case of myocardial infarction (heart attack). However, results have been mixed, with some studies showing promising outcomes while others indicate limited efficacy .

Recombinant PlGF-2 is widely used in research to study its role in angiogenesis and related processes. It is also used to investigate the mechanisms of various diseases and to develop potential therapeutic strategies. The availability of recombinant proteins like rhPlGF-2 has significantly advanced our understanding of these complex biological processes.